The world's population is growing older: by 2050, about 22% of people will be over 60. Aging remains the leading risk factor for neurodegenerative disease, and the brain loses vessels, myelin and the ability to birth new neurons along the way. It has long been known that the makeup of gut microbes shifts with age, but whether tinkering with the microbiome could reverse the cellular hallmarks of brain aging stayed unclear. This work sits somewhat apart: its closest neighbors in the archive study brain aging from other angles, such as maps of brain age or the effects of exercise, but nobody had directly tied microbial depletion to the rejuvenation of several cell types at once.
In 24-month-old mice (roughly 70-75 human years), the gut microbiota was wiped out over 30 days with a cocktail of four antibiotics: ampicillin, neomycin, vancomycin and metronidazole. For the first week the drugs were given by gavage twice a day, then added to drinking water for three weeks. Control mice received plain water. Cell nuclei were then isolated from the brain and RNA was sequenced from 45,089 individual nuclei from the hippocampus and cortex. In parallel, the researchers measured vessel density, the number of new neurons using the BrdU label, expression of myelin proteins and microglial activation. Separately, they checked the levels of 41 cytokines in plasma and brain, then manipulated eotaxin-1: giving it to mice on antibiotics, or blocking it with an antibody in mice not on antibiotics.
Clearing the microbiome caused sweeping transcriptional shifts across all major brain cell types without changing their relative numbers. In the cortex, blood vessel density rose and expression of the tight-junction protein claudin-5 increased, pointing to a strengthened blood-brain barrier. In the corpus callosum, the number of new oligodendrocytes and myelin content went up. In the hippocampal dentate gyrus, stem cell proliferation and the number of new neurons increased, while the number of senescent cells fell. Microglia became less activated: Iba1 area and the phagocytosis marker CD68 both shrank. In plasma, levels of 18 inflammatory molecules dropped; in the cortex, 21 did, with seven overlapping in both compartments. Among them, eotaxin-1 (CCL11) stood out: its level fell in both blood and brain. When recombinant eotaxin-1 was returned to mice during antibiotic treatment, the growth of vessels and neurogenesis were cancelled. Conversely, blocking eotaxin-1 with an antibody in old mice not given antibiotics reproduced many of the effects: vessels grew denser, neurogenesis increased, microglia calmed down, and the mice showed less anxiety in the open field and better memory for new objects.
This work stands out from its neighbors in the archive by being the first to link microbiome depletion with the simultaneous rejuvenation of vessels, myelin, neurogenesis and brain immune cells, whereas other studies focus on a single aspect of aging or use different interventions, such as exercise. The authors did not merely describe a correlation: they proved the causal role of one humoral factor, eotaxin-1. That moves the gut-brain axis out of the realm of general speculation and into the territory of concrete molecular targets.
The field could move toward identifying other microbial metabolites and cytokines that carry signals from the gut to the brain. Cell-type-specific maps of cytokine receptors and functional experiments blocking them will be needed. A separate question is which bacteria, or which of their products, trigger eotaxin-1 production in the gut, and whether the same effect can be achieved with probiotics or diet instead of antibiotics.
The results could shape the development of therapies for age-related cognitive decline and possibly for early stages of Alzheimer's disease, where dysbiosis has already been observed. Pharmacological blockade of eotaxin-1 or modulation of the microbiome could become a complement to existing strategies for preserving brain health.
Check whether the effect holds in female mice and in animals with a model of neurodegeneration. Determine which microbial strains or metabolites regulate eotaxin-1 levels, and test more selective interventions, such as transplanting specific bacteria or blocking the eotaxin-1 receptor.
The work touches on a fundamental problem in the biology of aging: whether age-related tissue changes are reversible under the influence of systemic signals. It links dysbiosis to cellular senescence and neuroinflammation, but leaves open the question of how conserved these mechanisms are in humans and whether the results can be carried over from mice to people.
Eotaxin-1 was first tied to brain aging in 2011, when its blood level correlated with memory decline in people, and giving the protein to young mice impaired their neurogenesis. Now it turns out its source may be not only the brain but also the gut, where eosinophils accumulate with age.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.